Central Asia Lumeichun Biotechnology Inc.

As of March 31, 2011, Central Asia Lumeichun Biotechnology Inc. carries a market capitalization of 157.76B, placing it among publicly traded companies globally. Its enterprise value stands at 157.76B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of March 31, 2011, Central Asia Lumeichun Biotechnology Inc. has 601.00 shares outstanding.

These figures are as of March 31, 2011.

As of March 31, 2011, Central Asia Lumeichun Biotechnology Inc. trades at an EV/EBITDA multiple of 283,747.42 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. Its EV/EBIT multiple of 1.56M values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 157.76B versus a market cap of 157.76B, with the gap driven by net debt and cash on the balance sheet.

These figures cover the twelve months ended March 31, 2011. Return on assets (ROA) is negative at -198.00, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 60.75, a quick read on workforce productivity versus industry peers.

As of the close on October 21, 2026, Central Asia Lumeichun Biotechnology Inc.'s stock has declined approximately 94.31% over the past 52 weeks. The 50-day moving average sits at 1.90, while the 200-day moving average is 2.71.

Over the twelve months ended March 31, 2011, Central Asia Lumeichun Biotechnology Inc. generated - - in revenue and converted that into -42.95M in net income, yielding earnings per share of -303.74. EBITDA reached 556,000.00, while operating income came in at -137,000.00.

These figures are as of March 31, 2011. Total book value stands at -7.31M, with working capital of -704,000.00 providing operational flexibility.

Central Asia Lumeichun Biotechnology Inc. produced -850,000.00 in operating cash flow over the twelve months ended March 31, 2011.

Central Asia Lumeichun Biotechnology Inc.'s most recent stock split took place on July 28, 2026 with a 500:1 split ratio.

As of March 31, 2011, Central Asia Lumeichun Biotechnology Inc. has an Altman Z-Score of 13,910.36, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.